Stempoint Capital’s Edgewise Therapeutics EWTX Stock Holding History

Stempoint Capital’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50,000	Closed	-$238K	–	65
2025 Q1	$238K	Buy	+50,000	New	+$1.31M	0.08%	53

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stempoint Capital's EWTX Position: Q2 2026 in Review

Stempoint Capital sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 290,864 shares — an estimated $9.16M sold.

Stempoint Capital first reported a position in EWTX in Q2 2024 and held it in 6 quarters. The position peaked at $9.16M in Q1 2026. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Stempoint Capital reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
Stempoint Capital sold 290,864 Edgewise Therapeutics shares in Q2 2026, an estimated $9.16M.
Stempoint Capital first reported a position in Edgewise Therapeutics in Q2 2024 and held it in 6 quarters.
Stempoint Capital's Edgewise Therapeutics position peaked at $9.16M in Q1 2026.
227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.